ESTRO 2023 - Abstract Book

S1737

Digital Posters

ESTRO 2023

Conclusion This study has demonstrated the feasibility of using LUTs to calculate microdosimetric quantities in a TPS that are comparable with Geant4. This is the first step in the implementation of biological models based on microdosimetry, such as MKM, within a TPS using microdosimetric quantities.

PO-1970 Primary renal cell cancer SBRT: a dosimetric evaluation of VMAT, Cyberknife and proton beam therapy

H. Green 1 , O. Byrne 2 , J. Henderson 2 , P. Bhudia 3 , V. Rompokos 4 , A. Mitra 5 , V. Khoo 1

1 Royal Marsden Hospital NHS Foundation Trust, Urology, Radiotherapy, London, United Kingdom; 2 Royal Marsden NHS Foundation Trust, Radiotherapy Physics, London, United Kingdom; 3 University College London Hospitals NHS Foundation Trust, Radiotherapy and Proton Beam Therapy Dosimetry, London, United Kingdom; 4 University College London Hospitals NHS Foundation Trust, Proton Beam Therapy Physics, London, United Kingdom; 5 University College London Hospitals NHS Foundation Trust, Urology. Radiotherapy, London, United Kingdom Purpose or Objective Stereotactic body radiotherapy (SBRT) for primary renal cell carcinoma (RCC) has increasing clinical data to support its use; however, the optimal dose regimes and delivery techniques are not known. RCC five-year net survival ranges from >85% and >70% for stage I and stage III respectively. However, mortality is higher in the older population. Many patients who require the use of radiotherapy are older, frail or have comorbidities that preclude them from invasive intervention. Radiotherapy is becoming an increasingly important treatment option to optimise in this underserved cohort. We carried out a retrospective observational analysis of primary RCC SBRT comparing linear accelerator (LINAC)-based volumetric modulated arc therapy (VMAT), Cyberknife (CK) and pencil-beam scanning (PBS) proton beam therapy (PBT).